Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).

摘要: Objective To better risk stratify patients, using baseline characteristics, to help optimise decision-making for men with moderate-to-severe lower urinary tract symptoms (LUTS) secondary benign prostatic hyperplasia (BPH) through a analysis of the Medical Therapy Prostatic Symptoms (MTOPS) trial. Patients and Methods After review literature, we identified potential factors BPH progression. Using bivariate tests in MTOPS data, determined which variables retained prognostic significance. We then used these Cox proportional hazard modelling to: i) more comprehensively study population based on pre-treatment parameters ii) determine strata stood benefit most from medical intervention. Results In all, 3047 were followed mean 4.5 years. found varying risks progression across quartiles. Baseline Impact Index score, post-void residual urine volume, serum prostate-specific antigen (PSA) level, age, American Urological Association Symptom maximum flow rate significantly correlate overall multivariable analysis. Conclusions Using permits estimation individual patient clinical benefits therapy. A novel decision tool analyses will allow clinicians weigh patient-specific against possible adverse effects given patient.